T he US Food and Drug Administration (FDA) and pharmaceutical company Novo Nordisk are now in an attempt to making more ...

The latest discovery in obesity medicine will be available in less invasive creams and patches, known as transdermal drug ...

The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout ...

A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug ...

"With the FDA announcing the resolution of shortages for Semaglutide (Wegovy, Ozempic) and Tirzepatide (Zepbound, Mounjaro), compounding pharmacies must halt production of these medications. This ...

But this doesn't negate the drugs' potential downsides, one of which has doctors urging patients to "proceed with caution" ...

The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk (NYSE: NVO) has seen revenue soar in recent years thanks to two drugs that have helped people around the world ...

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

A unique Novo Nordisk legal challenge to the Medicare drug pricing program could have big implications for the pharma ...